X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (240) 240
index medicus (199) 199
hematology (191) 191
multiple myeloma (141) 141
male (130) 130
female (125) 125
middle aged (121) 121
aged (113) 113
oncology (112) 112
adult (95) 95
multiple myeloma - drug therapy (90) 90
bortezomib (76) 76
multiple myeloma - therapy (69) 69
stem-cell transplantation (63) 63
treatment outcome (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (55) 55
prognosis (51) 51
care and treatment (50) 50
thalidomide (49) 49
survival (48) 48
transplantation (46) 46
aged, 80 and over (44) 44
dexamethasone (44) 44
chemotherapy (42) 42
thalidomide - administration & dosage (42) 42
multiple myeloma - mortality (41) 41
therapy (41) 41
lenalidomide (39) 39
multiple myeloma - diagnosis (39) 39
cancer (38) 38
abridged index medicus (37) 37
disease-free survival (37) 37
leukemia (37) 37
multiple myeloma - pathology (36) 36
hemic and lymphatic diseases (35) 35
antineoplastic agents - therapeutic use (34) 34
dexamethasone - administration & dosage (34) 34
stem cells (31) 31
transplantation, autologous (31) 31
antineoplastic combined chemotherapy protocols - adverse effects (29) 29
diagnosis (29) 29
multiple myeloma - complications (28) 28
retrospective studies (28) 28
patients (27) 27
stem cell transplantation (27) 27
thalidomide - analogs & derivatives (27) 27
autologous transplantation (26) 26
research (26) 26
bone marrow (25) 25
follow-up studies (25) 25
hematopoietic stem cell transplantation (25) 25
multiple myeloma - genetics (25) 25
risk factors (25) 25
hematology, oncology and palliative medicine (24) 24
lenalidomide plus dexamethasone (24) 24
elderly-patients (23) 23
melphalan (23) 23
thalidomide - adverse effects (23) 23
adolescent (22) 22
drug therapy (22) 22
recurrence (22) 22
survival analysis (22) 22
clinical trials (21) 21
combined modality therapy (21) 21
medical research (21) 21
multiple-myeloma (21) 21
remission induction (21) 21
melphalan - administration & dosage (20) 20
analysis (19) 19
kaplan-meier estimate (19) 19
myeloma (19) 19
neoplasm staging (19) 19
survival rate (19) 19
thalidomide - therapeutic use (19) 19
health aspects (18) 18
cell biology (17) 17
medicine & public health (17) 17
young adult (17) 17
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
peripheral neuropathy (16) 16
prednisone (16) 16
time factors (16) 16
boronic acids - administration & dosage (15) 15
clinical medicine (15) 15
consolidation therapy (15) 15
immunology (15) 15
minimal residual disease (15) 15
protein kinase inhibitors - therapeutic use (15) 15
pyrazines - administration & dosage (15) 15
transplants & implants (15) 15
chronic myeloid leukemia (14) 14
cyclophosphamide (14) 14
dexamethasone - adverse effects (14) 14
impact (14) 14
klinisk medicin (14) 14
medical and health sciences (14) 14
medicin och hälsovetenskap (14) 14
medicine, experimental (14) 14
plus dexamethasone (14) 14
positron-emission-tomography (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9758, pp. 2075 - 2085
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 895 - 905
In patients 65 or younger with multiple myeloma, high-dose consolidation therapy was associated with longer survival and more myelotoxicity than... 
MEDICINE, GENERAL & INTERNAL | PREDNISONE | PLUS DEXAMETHASONE | INDUCTION THERAPY | LENALIDOMIDE | INITIAL TREATMENT | RANDOMIZED CONTROLLED-TRIAL | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Transplantation, Autologous | Consolidation Chemotherapy | Antineoplastic Agents, Alkylating - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Adult | Maintenance Chemotherapy | Neutropenia - chemically induced | Thalidomide - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Aged | Antineoplastic Agents, Alkylating - adverse effects | Stem Cell Transplantation - adverse effects | Complications and side effects | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Research | Health aspects | Autografts | Chemotherapy | Cell survival | Transplants & implants | Melphalan | Stem cell transplantation | Death | Prednisone | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
by Cavo, M
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 2, pp. 99 - 101
In this issue of Blood, Mikhael et al report the results of a phase 1b study of isatuximab combined with standard-dose pomalidomide and dexamethasone in... 
MULTIPLE-MYELOMA | DEXAMETHASONE | BORTEZOMIB | HEMATOLOGY
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2017, Volume 92, Issue 1, pp. 82 - 87
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1055 - 1066
Journal Article
Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 4, pp. 375 - 376
In this issue of Blood, Mateos et al report that bortezomib plus melphalan and prednisone (VMP) and lenalidomide plus low-dose dexamethasone (Rd) administered... 
MULTIPLE-MYELOMA | PREDNISONE | LENALIDOMIDE | INITIAL TREATMENT | THALIDOMIDE | HEMATOLOGY | MELPHALAN | Dexamethasone - therapeutic use | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Female | Male | Antineoplastic Agents - therapeutic use | Melphalan - therapeutic use
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2013, Volume 8, Issue 9, p. e75531
Journal Article
Journal Article